Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

NCT06168409 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06168409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06168409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
March 1, 2024
Completion date
August 17, 2025
Enrollment
218 (actual)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

resistant hypertension